This dataset contains image annotations derived from the NCI Clinical Trial "Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor (AREN0534)”.  The key objective of this project is to generate a large and highly curated imaging dataset of pediatric Wilms tumor patients with annotations suitable for cancer researchers and AI developers.

Annotation Protocol

For each patient, every DICOM Study and DICOM Series was reviewed to identify and annotate the clinically relevant time points and sequences. In a typical patient the following time points will be annotated:

1. Pre-surgical CT chest and CT/MRI abdomen
2. CT chest and/or CT/MRI abdomen at 6 weeks
3. Possible CT/MRI abdomen at 12 weeks. 
4. Any negative imaging included past 12 weeks was annotated as negative. If any included imaging past 12 weeks is positive for tumor, the last positive exam was annotated. 

In a typical patient the following annotation rules were followed:

1. The primary renal tumor(s) were annotated on the post-contrast axial series. Normal renal parenchyma were excluded. 
2. A maximum of 5 lesions were annotated per patient scan (timepoint); no more than 2 per organ. The same 5 lesions were annotated at each time point.  RECIST 1.1 principles were followed for lesion annotation, however, if <5 lesions measuring >1 cm were present, then smaller lesions were annotated, again up to 2 lesions per organ or 5 lesions per patient scan. Bone lesions were included if other lesions were not present. 
3. Lesions were labeled separately.
4. Seed points were automatically generated but reviewed by a radiologist.

At each time point:

1. A seed point (kernel) was created for each segmented structure. The seed points for each segmentation are provided in a separate DICOM RTSS file. 
2. SNOMED-CT “Anatomic Region Sequence” and “Segmented Property Category Code Sequence” and codes were inserted for all segmented structures.
3. Imaging time point codes were inserted to help identify each annotation in the context of the clinical trial assessment protocol. 
   1. (255235001, SCT, “Pre-dose”)
   2. (262502001, SCT, "Post-chemotherapy") #1
   3. (262502001, SCT, "Post-chemotherapy") #2
   4. (262061000, SCT, "Post-operative")
   5. (262502001, SCT, "Post-chemotherapy") #3
   6. (262502001, SCT, "Post-chemotherapy") #4
1. “Clinical Trial Time Point ID” was used to encode time point type using one of the following strings as applicable: “pre-dose”, “post-chemotherapy”, or “post-operative”.
2. Content Item in “Acquisition Context Sequence” was added containing "Time Point Type" using Concept Code Sequence (0040,A168) selected from: